Portfolio company Apnimed's shares jumped after an upsized US IPO.
Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, particularly obstructive sleep apnea (OSA)
Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, particularly obstructive sleep apnea (OSA).